The effect of vasopressin treatment on learning in Down's syndrome.
Vasopressin is reported to enhance learning and memory in animal models. In 9 Down's syndrome patients DDAVP, a vasopressin derivative, was administered for 10 days, 40 micrograms per day, in a double-blind randomized crossover design. A visual-verbal paired associate learning test showed a not significant tendency for benefit with DDAVP. Word List memory was not improved with DDAVP treatment.
D000293:Adolescent; D000328:Adult; D001127:Arginine Vasopressin / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D004311:Double-Blind Method; D004314:Down Syndrome / Q000188:drug therapy*; D006801:Humans; D008568:Memory; D010153:Paired-Associate Learning
D001127:Arginine Vasopressin; D003894:Deamino Arginine Vasopressin